MolecuLight Optimizes Burn Care with Advanced Bacterial Imaging at the American Burn Association 2025 Annual Meeting
07.08.2025 - 18:06:43 | prnewswire.co.uk
is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.
View original content:https://www.prnewswire.co.uk/news-releases/moleculight-optimizes-burn-care-with-advanced-bacterial-imaging-at-the-american-burn-association-2025-annual-meeting-302422559.html
Hol dir jetzt den Wissensvorsprung der Aktien-Profis.
Seit 2005 liefert der Börsenbrief trading-notes verlässliche Aktien-Empfehlungen - Dreimal die Woche, direkt ins Postfach. 100% kostenlos. 100% Expertenwissen. Trage einfach deine E-Mail Adresse ein und verpasse ab heute keine Top-Chance mehr. Jetzt abonnieren.
Für. Immer. Kostenlos.
Für. Immer. Kostenlos.
CA00765C1086 | MOLECULIGHT | boerse | 67953975 |

